Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | PI4KA | P42356 | 1/20 | 0.38 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.38 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29648618 | 1.00 | KDM4E (0.49) | KDM4EHSD17B10HPGDNPC1RAB9A | |
| SCHEMBL9267190 | 0.75 | PARP1 (0.39) | KDM4EALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL1460808 | 0.74 | MAOB (0.42) | KDM4EALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL17574484 | 0.74 | MAOB (0.39) | KDM4ENPC1ALDH1A1LMNAMEN1 | |
| SCHEMBL1462783 | 0.72 | ALDH1A1 (0.39) | KDM4EHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL8649431 | 0.72 | NPC1 (0.44) | KDM4EHSD17B10HPGDNPC1RAB9A | |
| SCHEMBL29790789 | 0.72 | EGFR (0.42) | KDM4EHPGDNPC1RAB9AALDH1A1 | |
| SCHEMBL30277469 | 0.72 | MAOB (0.50) | KDM4EALDH1A1PDE10ANCF1 | |
| SCHEMBL361719 | 0.71 | KDM4E (0.54) | KDM4EHSD17B10HPGDNPC1RAB9A | |
| SCHEMBL29974345 | 0.71 | KDM4E (0.54) | KDM4EHSD17B10HPGDNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152659-A1 | Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-08-05 | — | — | US | claimed |
| EP-1177797-A9 | NOVEL USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-15 | — | — | EP | claimed |
| EP-1177797-A1 | NOVEL USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-06 | — | — | EP | claimed |
| EP-0745154-B1 | MULTICOMPONENT SYSTEM FOR MODIFYING, DECOMPOSING OR BLEACHING LIGNIN, LIGNIN-CONTAINING MATERIALS OR SIMILAR SUBSTANCES AND METHOD OF USING THIS SYSTEM | LIGNOZYM GMBH (DE) | 1998-09-16 | — | — | EP | claimed |
| EP-0845026-A1 | MULTICOMPONENT SYSTEM FOR USE WITH DETERGENT SUBSTANCES | CALL, Hans-Peter Dr. (DE) | 1998-06-03 | — | — | EP | claimed |
| WO-1997048786-A1 | MULTICOMPONENT SYSTEM FOR USE WITH DETERGENT SUBSTANCES | CALL HANS PETER (DE) | 1997-12-24 | — | — | WO | claimed |
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| EP-3331532-B1 | SUBSTITUTED AMINOQUINAZOLINE COMPOUNDS AS A2A ANTAGONIST | MERCK SHARP & DOHME LLC (US) | 2022-12-07 | — | — | EP | disclosed |
| US-9771362-B2 | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-09-26 | — | — | US | disclosed |
| EP-2938344-B1 | PIPERAZINE-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME (US) | 2017-06-21 | — | — | EP | disclosed |
| US-20170066762-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-03-09 | — | — | US | disclosed |
| US-9394301-B2 | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-07-19 | — | — | US | disclosed |
| US-20150246915-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-09-03 | — | — | US | disclosed |
| US-5196421-A | Treatment of neurological disorders | ELI LILLY AND COMPANY (US) | 1993-03-23 | — | — | US | disclosed |
| EP-0518530-A2 | Improvements in or relating to excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 1992-12-16 | — | — | EP | disclosed |
| US-5153196-A | Administering for reduction of neurotransmission in nervous system disorders | ELI LILLY AND COMPANY (US) | 1992-10-06 | — | — | US | disclosed |
| US-4713383-A | ADENOSINE AND BENZODIAZEPINE ANTAGONISTS | CIBA-GEIGY CORPORATION (US) | 1987-12-15 | — | — | US | disclosed |
| US-4713383-A | ADENOSINE AND BENZODIAZEPINE ANTAGONISTS | CIBA-GEIGY CORPORATION (US) | 1987-12-15 | — | — | US | disclosed |
| US-4053600-A | ANTIINFLAMMATORY AGENTS, HYPOTENSIVE AGENTS | SANDOZ, INC. (US) | 1977-10-11 | — | — | US | disclosed |
| US-4053600-A | ANTIINFLAMMATORY AGENTS, HYPOTENSIVE AGENTS | SANDOZ, INC. (US) | 1977-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152659-A1 | Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist | ADORA2A, ADORA1, ADORA2B | KDM4E 4617/4885HSD17B10 3368/4885HPGD 1304/4885 |
| US-20150246915-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | AXL, TYRO3, FLT3 | KDM4E 1582/4885HSD17B10 4831/4885HPGD 3521/4885 |
| US-20170066762-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | AXL, TYRO3, FLT3 | KDM4E 1582/4885HSD17B10 4831/4885HPGD 3521/4885 |
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | AHR, HRH4, HRH1 | KDM4E 1364/4885HSD17B10 3997/4885HPGD 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.